Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice.

Introduction: This study assessed mutation detection and functional characteristics across 13 distinct technologies and assays available in clinical practice, in a blinded manner.

Methods: Five distinct -mutant cell lines were used to study five clinically relevant mutations: p.G12C, p.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Purpose: A urinary assay for PCA3, an mRNA that is highly over expressed in prostate cancer cells, has shown usefulness as a diagnostic test for this common malignancy. We further characterized PCA3 performance in different groups of men and determined whether the PCA3 score could synergize with other clinical information to predict biopsy outcome.

Materials And Methods: Prospectively urine was collected following standardized digital rectal examination in 570 men immediately before prostate biopsy.

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.

Background: Measurement of prostate cancer gene 3 (PCA3) mRNA normalized to prostate-specific antigen (PSA) mRNA in urine has been proposed as a marker for prostate cancer.

Methods: We investigated pre-analytical effects, analytical performance, and diagnostic accuracy of a quantitative assay for PCA3.

Results: Urine specimens collected without prostate manipulation demonstrated low informative rates.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Objectives: Men with elevated serum prostate-specific antigen (PSA) levels and negative prostate biopsy findings present a dilemma because of the lack of an accurate diagnostic test. We evaluated the potential utility of the investigational prostate cancer gene 3 (PCA3) urine assay to predict the repeat biopsy outcome.

Methods: Urine was collected after digital rectal examination (three strokes per lobe) from 233 men with serum PSA levels persistently 2.

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Background: Prostate cancer gene 3 (PCA3) encodes a prostate-specific mRNA that has shown promise as a prostate cancer diagnostic tool. This report describes the characterization of a prototype quantitative PCA3-based test for whole urine.

Methods: Whole-urine specimens were collected after digital rectal examination from 3 groups: men scheduled for prostate biopsy (n = 70), healthy men (<45 years of age with no known prostate cancer risk factors; n = 52), and men who had undergone radical prostatectomy (n = 21).

Substrate-induced changes in the ammonia channel for imidazole glycerol phosphate synthase.

IGP synthase is a glutamine amidotransferase that incorporates ammonia derived from glutamine into the unusual nucleotide, N(1)-[(5'-phosphoribulosyl)-formimino]-5-aminoimidazole-4-carboxamide ribonucleotide (PRFAR) to form 5'-(5-aminoimidazole-4-carboxamide) ribonucleotide (AICAR) and imidazole glycerol phosphate (IGP). A common feature of all glutamine amidotransferases is the upregulation of glutamine hydrolysis in the presence of an acceptor substrate. A refined assay system was developed to establish that Saccharomyces cerevisae IGP synthase shows a 4900-fold stimulation of glutaminase in the presence of the substrate acceptor PRFAR.